Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.

Haematologica - 1 Jul 2024

Xu Linlin, Shadman Mazyar, Flinn Ian W, Levy Moshe Y, Porter Ryan, Burke John M, Zafar Syed F, Cultrera Jennifer L, Misleh Jamal, Kingsley Edwin C, Yimer Habte A, Freeman Benjamin, Chaudhry Arvind, Tumula Praveen K, Gandhi Mitul D, Crescenzo Rocco, By Kunthel, Cohen Aileen, Chen Dih-Yih, Idoine Adam, Manda Sudhir, Sharman Jeff P, Ramakrishnan Vanitha

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Aminobutyrates
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Piperidines

Share to Pyrazines

Share to Pyrazoles

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 38268449
DOI: 10.3324/haematol.2023.283861
PMCID: PMC11215392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.PMID 38268449Read ↗

Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.Semantic proximity Read ↗

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemiaSemantic proximity Read ↗

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaSemantic proximity Read ↗

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.Semantic proximity Read ↗

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibSemantic proximity Read ↗

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.Semantic proximity Read ↗

Distinct immune and genomic signatures predict resistance to ibrutinib therapy in Waldenström macroglobulinemiaSemantic proximity Read ↗

Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.Semantic proximity Read ↗

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.